EFFEKTIVNOST' KOMBINIROVANNOY ANTIGIPERTENZIVNOY TERAPII ZhENShchIN S ARTERIAL'NOY GIPERTENZIEY I IShEMIChESKOY BOLEZN'Yu SERDTsA, VKLYuChAYuShchEY RAZLIChNYE BLOKATORY RENIN-ANGIOTENZINOVOY SISTEMY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article presents the results of the study involving 100 women with arterial hypertension (AH) and stable coronary heart disease (CAD); the study was aimed to the evaluation of antihypertensive efficacy of ACE inhibitor zofenopril and angiotensin II receptor blocker valsartan using once a day and twice a day administration. Follow-up period was 24 weeks. It has been shown that combined antihypertensive therapy based on administration of valsartan twice a day may have advantages over the use of zofenopril in women with a combination of arterial hypertension and stable coronary artery disease.

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Wyskida K., Jura-Szoltys E., Smertka M., et al. Factors that favor the occurrence of cough in patients treated with ramipril-a pharmacoepidemiological study. Med Sci Monit. 2012; 18(9): 21-8.
  2. Dahlof B, Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan intervention for Endpoint reduction in hypertension study (LiFE): A randomized trial against atenolol. Lancet. 2002; 359: 995-1003.
  3. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5-26.
  4. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2008; 7(6). Приложение 4.
  5. Capri Workshop Group. Hormones and cardiovascular health in women. Human Report Update. 2006; 12: 483-97.
  6. Рекомендации по снижению общего риска развития заболеваний и осложнений у женщин. М., 2010.
  7. Reckelhoff J.F. Basic research into the mechanisms responsible for postmenopausal hypertension. int. J. Clin. Pract. 2004; 58(suppl. 139): 13-9.
  8. Dzan V., Sasamura H., Hein L. Heterogeneity of angiotensin synthetic pathways and subtypes: Physiological and pharmacological implication.J. Hypertension. 1993; 11: 13-8.
  9. Urata H., Boehm K.D., Philip A. et al. Cellular localization and regional dis-tribution of an angiotensin ii-forming chymase in the heart. J Clin invest. 1993; 91: 1269-81.
  10. Nishimura H., Hoffman S., Baltatu O. et al. Angiotensin i converting enzyme and chymase in cardiovascular tissues. Kidney int. 1996; 49: 18-23.
  11. Denton K.M., Hilliard L.M., Tare М. Sex-Related Differences in Hypertension: Seek and Ye Shall Find. Hypertension. 2013; 62: 674-77.
  12. Brown R.D., Hilliard L.M., Head G.A., et al. Sex differences in the pressor and tubuloglomerular feedback response to angiotensin ii. Hypertension. 2012; 59: 129-35.
  13. McCarthy C.A., Widdop R.E., Denton K.M., Jones E.S. Update on the angiotensin AT(2) receptor. Curr. Hypertens Rep. 2013; 15: 25-30.
  14. Скибицкий В.В., Медведева Ю.Н., Шухардина Е.Л. и др. Факторы риска и структура кардиоваскулярной патологии у женщин в климаксе различного генеза. Проблемы женского здоровья. 2007; 3(2): 21-8.
  15. Hermida R.C., Ayala D.E., Mojon A., et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing Chronobiol int. 2011; 28(7): 601-10.
  16. Yoshida H., Shimizu M., Ikewaki K. et al. Sex differences in effects of valsartan administration on cardiovascular outcomes in hypertensive patients: findings from the Jikei Heart Study. J. Hypertens. 2010; 28(6): 1150-57.
  17. Mazzolai L., Daven V., Centeno C., Nussberger J., Brunner H.R., Burnier M. Assessment of angiotensin ii receptor blockade in humans using a standardized angiotensin ii receptor-binding assay. Am. J. Hypertens. 1999; 12(12 Pt1-2): 1201-08.
  18. Asmar R. Targeting effective blood pressure control with angiotensin receptor blockers. int J. Clin. Pract.2006; 60; 3: 315-20.
  19. Ando H., Ushijima K., Hosohata K., et al. Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. Br. J. Clin. Pharmacol. 2013; 75(2): 415-22.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>